Company intelligence / Profile preview
BioRay Biotech Co., Ltd.
Pingtung, Pingtung County, Taiwanbio-ray.com.tw ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
BioRay has multiple products in development with BR105 (SIRPα antibody) in clinical trials in China and approved for clinical trials by the FDA, and BR111 (ROR1-targeting dual-epitope ADC) approved for clinical trials by NMPA. The company also has marketed products.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Functional probioticsmedicinal fungiimmune cell preparationsmonoclonal antibodiesantibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on BioRay Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioRay Biotech Co., Ltd..